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Background. Meningioma patients are known to face cognitive deficits before and after surgery. We examined in-
dividual changes in cognitive performance over time and identified preoperative predictors of cognitive function-
ing 12 months after surgery in a large sample of meningioma patients.
Methods. Patients underwent neuropsychological assessment (NPA) using CNS Vital Signs 1 day before (T0) and 
3 (T3) and 12 (T12) months after surgery. Patients’ sociodemographically corrected scores on 7 cognitive domains 
were compared with performance of a normative sample using one-sample z tests and chi-square tests of indepen-
dence. Reliable change indices with correction for practice effects were calculated for individual patients. Linear 
mixed effects models were used to identify preoperative predictors of performance at T12.
Results. At T0, 261 patients were assessed, and 229 and 82 patients were retested at T3 and T12, respectively. 
Patients showed impaired cognitive performance before and after surgery, and although performance improved 
on the group level, cognitive scores remained significantly lower than in the normative sample up to T12. On the in-
dividual level, performance remained stable in the majority of patients. Better preoperative performance, younger 
age, male sex, and higher educational level predicted better late cognitive performance.
Conclusions. Meningioma patients face serious and persistent pre- and postsurgical cognitive deficits. A preop-
erative NPA together with sociodemographic characteristics may provide valuable information on the late cogni-
tive outcome of individual meningioma patients. These results can help to inform patients and clinicians on late 
cognitive outcomes at an early stage, and emphasizes the importance of presurgical NPA and timely cognitive 
rehabilitation.
Key Points
1. Meningioma patients face cognitive deficits before and after surgery.
2. Performance improves after surgery but remains significantly lower than in controls.
3. Late cognitive performance is best predicted by preoperative cognitive performance.
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Tumor resection is the preferred treatment for the vast 
majority of patients with intracranial meningioma.1 
However, meningioma patients already suffer from 
deficits in several cognitive domains before surgery.2 
Surgical resection of the meningioma has been found 
to improve cognitive performance of patients, but some 
postoperative cognitive deficits continue to exist, as sig-
nificant cognitive impairments are reported up to 4 years 
after surgery.2–11 However, to date, preoperative cogni-
tive functioning has not often been examined, thereby 
limiting statements about changes in cognitive perfor-
mance over time. The few studies that explored changes 
over time (following a preoperative assessment up to 
9  months after surgery) predominantly demonstrated 
improved cognitive performance.6–10,12,13 Yet, study results 
were presented on the group instead of individual patient 
level, fairly simple measures of change in performance 
were adopted (eg, raw mean difference scores), and prac-
tice effects of repeated assessments were often not cor-
rected for.14
Despite the fact that extensive cognitive deficits in 
meningioma patients have been described by several 
studies, research into predictors of cognitive performance 
in these patients remains limited.2 Mixed findings were 
reported with respect to the association between cogni-
tive performance and, among others, tumor location and 
psychological factors (ie, anxiety and depression).2,3,5,13,15 
Moreover, preoperative predictors of late cognitive out-
comes have only minimally been addressed in menin-
gioma patients, which is remarkable given the negative 
impact of cognitive deficits on, for example, returning to 
social and professional activities after meningioma sur-
gery.5,16,17 Information on the sociodemographic, clinical, 
psychological, or cognitive characteristics of patients who 
are at risk for cognitive impairment in the long term after 
surgery may help to inform patients and clinicians at an 
earlier stage.
We explored cognitive functioning using a computerized 
neuropsychological battery in a large sample of meningi-
oma patients one day before, and 3 and 12 months after 
surgery. Changes in performance were assessed at the 
group level, as well as at the individual level using reli-
able change indices (RCIs) for each of the two time inter-
vals. Additionally, we sought to identify preoperative 




The present study was part of a prospective longitudinal 
study in which brain tumor patients admitted for surgical 
resection between November 2010 and June 2017 under-
went neuropsychological assessment (NPA) one day 
before surgery (T0) and 3 months after surgery (T3) as part 
of standard clinical neuro-oncological care. An (approxi-
mately) 12-month postoperative follow-up assessment 
(T12) was added as from January 2014 for research pur-
poses in order to explore long-term cognitive functioning.
Patients
Cases eligible for the current study were patients who 
underwent initial surgical resection, and who were histo-
pathologically diagnosed with a WHO grade I or II meningi-
oma. We excluded patients under the age of 18 years, with 
a history of intracranial neurosurgery, intraosseous menin-
gioma, a recent history (≤2 y) of severe psychiatric or neu-
rologic disorders, other major medical illnesses in the year 
prior to surgery (eg, cancer), a lack of basic proficiency 
in Dutch, or/and the inability to undergo the NPA due to 
severe visual, motor, or cognitive problems. In addition, 
patients who participated in the cognitive rehabilitation 
studies that were simultaneously running were excluded 
from the current study if they had been randomly assigned 
to the intervention (ie, rehabilitation) group.18,19 The cutoff 
for the maximum time interval between T0 and T12 assess-
ment was set at 21 months.
All patients provided written informed consent. The 
study was approved by the Medical Ethics Committee (file 
NL41351.008.12). There is considerable overlap between 




Patients were assessed per standardized protocol at all 
three timepoints, including a checklist and standardized 
Importance of the Study
Meningioma patients showed significantly worse cog-
nitive performance before and after surgery compared 
with healthy controls. Although performance improved 
over time on the level of the whole group, cognitive 
scores remained significantly lower than in controls 
up to 12  months after surgery. On the individual level, 
performance remained stable in the majority of menin-
gioma patients. Preoperative cognitive performance of 
meningioma patients turned out to be the best predictor 
for late performance, and sociodemographic charac-
teristics (ie, age, sex, and education) were predictive 
for cognitive outcomes in meningioma patients. These 
results can help to inform patients and clinicians on 
late cognitive status at an early stage, and emphasize 
the need for presurgical neuropsychological assess-
ments and timely cognitive rehabilitation in meningioma 
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interview at T0 (ie, for obtaining and verifying sociode-
mographic information such as age, sex, and educational 
level). The highest completed level of education was clas-
sified according to the Dutch Verhage scale.21 Its 7 catego-
ries were merged into 3 categories: low educational level 
(Verhage 1–4: primary level education or lower), middle 
educational level (Verhage 5: completion of average level 
secondary education), and high educational level (Verhage 
6, 7: high level secondary education or university degree).
Clinical characteristics
Clinical information was obtained from the electronic 
medical charts. A  histopathological diagnosis was pro-
vided following surgery and categorized as WHO grade 
I or II meningioma.22 By means of a preoperative contrast-
enhanced T1 weighted MRI, tumor location (ie, supratento-
rial vs infratentorial), and further classified as frontal (ie, 
frontal, frontal-temporal, and frontal-parietal) versus non-
frontal involvement, hemisphere (ie, right, left, bilateral), 
and the number of tumors were identified. In addition, we 
determined preoperative total tumor volume (in mm3) of 
the meningioma operated on using semi-automatic seg-
mentations performed in ITK-SNAP (www.itksnap.org23), 
followed by minor manual adjustments to lesion mar-
gins. The American Society of Anesthesiologists (ASA) 
score was considered as a physical status classification, 
ranging from ASA I (patient completely healthy) to ASA V 
(moribund patient).24 ASA score was considered dichoto-
mous: patients within ASA categories I and II were consid-
ered healthy, whereas patients within categories III and IV 
were considered to have substantial comorbidities. Anti-
epileptic drugs, corticosteroids, benzodiazepines, opioids, 
antipsychotics, stimulants, and/or antidepressants were 
recorded as psychotropic medications.
Psychological characteristics
Anxiety and depression were assessed using the Dutch 
translation of the Hospital Anxiety and Depression Scale 
(HADS).25,26 This self-report instrument consists of 14 
items: each subscale (anxiety and depression) includes 7 
items, resulting in a score of 0–21 for each subscale, with 
higher scores representing more symptoms. The Dutch 
translation of the HADS has good psychometric qualities, 
with Cronbach’s alphas of .81–.84 and .71–.86 for the anxi-
ety and depression subscales, respectively.26
Cognitive performance
The formal Dutch translation of the computerized neuro-
psychological battery CNS Vital Signs (VS) was used to 
examine cognitive performance. CNS VS comprises 7 
neuropsychological tests, yielding measures of perfor-
mance in 11 cognitive domains.27 Since the measures 
of performance for some domains are largely based on 
scores on the same tests, we considered only the follow-
ing 7 cognitive domains: Verbal Memory, Visual Memory, 
Processing Speed, Psychomotor Speed, Reaction Time, 
Complex Attention, and Cognitive Flexibility (Table 1). 
NPAs were performed using the CNS VSX local soft-
ware app, on a laptop running a 64-bit operating system. 
A  well-trained test technician remained present during 
each assessment.
After completing the battery, which takes approximately 
30–40 minutes, raw scores for each domain are automati-
cally provided by the program (Table 1). Since effects of 
age, education, and sex on CNS VS performance were 
demonstrated in a Dutch normative sample (N = 158; age 
20–80 y, education 10–26 y, assessed at baseline and at 
3- and 12-month follow-up), raw cognitive domain scores 
were converted into sociodemographically adjusted z 
scores (see Rijnen et al28 for a detailed description). In addi-
tion, effects of practice were found in the Dutch normative 
sample between T0 and T3. Test scores at T3 and T12 were 




Descriptive and comparative analyses (ie, one-sample 
z-tests, chi-square tests of independence) were performed 
to explore potential differences in baseline sociodemo-
graphic, clinical, and psychological variables of the differ-
ent patient samples assessed at T0, T3, and T12 and the T12 
dropouts.
Pre- and postoperative cognitive performance
Cognitive performance in individual patients was defined 
as impaired if a z score was ≤−1.50.30 The numbers and per-
centages of patients scoring impaired were calculated for 
all cognitive domains at all timepoints. In addition, a chi-
square test of independence was conducted to compare 
the proportions of meningioma patients with impaired per-
formance (per domain, per timepoint) with the proportions 
of participants in the normative sample with impaired per-
formance (ie, to test whether such deviant scores occurred 
significantly more frequently in meningioma patients than 
in controls).
To explore mean performance on the cognitive domains 
of meningioma patients compared with the normative con-
trols at T0, T3, and T12, one-tailed one-sample z-tests were 
performed (test values: mean [M] z = 0, standard deviation 
[SD] = 1). The mean z score for each domain (ie, the differ-
ence between the patient sample and the normative sam-
ple in terms of SDs) is comparable to Glass’s delta (∆) effect 
size (ES) when calculated according the following formula: 
Meanpatients − Meancontrols/SDcontrols. ES ≤0.50, between 0.51 
and 0.79, and ≥0.80 respectively reflected small, medium, 
and large effects.31
Changes in individual and group cognitive performance 
over time
Changes in cognitive performance over time in individ-
ual patients were examined using RCIs. RCIs illustrate 
reliable changes in performance in individual patients, 
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A  standardized regression-based RCI as described by 
Maassen, Bossema, and Brand32 was adopted. Rijnen 
et  al29 described details with regard to the RCI for 
changes in CNS VS performance specifically, based upon 
results on repeated testing in a Dutch normative sample 
from baseline (n = 158) to 3- (n = 133) and 12-month (n 
= 77) follow-up. In the current study, change was defined 
as RCI values exceeding  ±  1.645 (corresponding with a 
two-tailed alpha of 0.10%, 90% confidence interval), with 
positive values indicating improved performance and 
negative values representing declines. The numbers 
of patients with improved, stable, and declined perfor-
mance were counted for each domain at the two time 
intervals. Additionally, chi-square tests of independence 
were conducted for the separate domains to compare the 
proportion of “changers” (improvers or decliners) in the 
meningioma patients to the proportion of “changers” in 
the normative sample (ie, again to test whether changes 
occurred significantly more frequently in patients than 
in controls). In case of statistical significance, standard-
ized residuals were used to interpret chi-square tables 
as to which cells (ie, which change category: improved, 
stable, declined) contributed to the significant result. We 
assessed the amount of overlap between patients with 
solely improved or declined performance between both 
T0–T3 and T3–T12 (ie, to determine whether changes 
comprise further improvements/deterioration in the 
same patients, or “new” changes in patients who showed 
stable performance over the other time interval).
Changes over time (ie, between T0–T3 and T3–T12) 
on the mean group level were assessed using the lin-
ear mixed effects models (LMEMs) (described in detail 
below).
Predictors of late cognitive impairment
LMEMs for repeated measurements were fitted to exam-
ine preoperative predictors of late (T12) cognitive func-
tioning in meningioma patients for each domain. To 
estimate the model parameters, the restricted maximum 
likelihood estimate method was used. The Akaike infor-
mation criterion and Bayesian information criterion were 
used to estimate model fit. A  heterogeneous first-order 
autoregressive covariance structure was selected, the 
random effect was subject ID, and predictors were entered 
as fixed effects into the model. Outcome measures were 
the z scores for the separate cognitive domains at T12. 
Predictors included timepoint (T0, T3, T12), the number 
of months between T0 and T12 (ranging 8–21 months), 
sociodemographic (age, sex, educational level), clinical 
(tumor location: hemisphere, supra- versus infratentorial, 
frontal versus nonfrontal, number of meningioma, tumor 
volume, ASA score, medication use), and psychological 
(anxiety and depression) variables. In addition, T0 scores 
of all domains were included in the LMEMs as cognitive 
predictors except the T0 scores of the predicted domain 
itself. Including T0 performance of a specific domain 
itself as a predictor (in addition to the inclusion of T0 
 
Table 1 Supplementary material on CNS Vital Signs
Cognitive 
Domain
CNS VS Test Domain Score Calculations Description
Verbal Memory Verbal memory test 
(VBM)
VBM direct  correct hits + VBM 
direct  correct passes + VBM 
delayed correct hits + VBM 
delayed correct passes
Learning a list of 15 words, with a direct recognition, and 
after 6 more tests a delayed recognition trial
Visual Memory Visual memory test 
(VIM)
VIM direct correct hits + VIM 
direct correct passes + VIM 
delayed correct hits + VIM 
delayed correct passes
Learning a list of 15 geometric figures, with a direct recog-
nition, and after 6 more tests a delayed recognition trial
Processing 
Speed
Symbol digit coding 
(SDC)
SDC correct responses – SDC 
errors
Number 1 to 9 correspond to different symbols. As many 
correct numbers as possible have to be filled out under-
neath the presented symbols in 90 seconds
Psychomotor 
Speed
Finger tapping test (FTT) 
Symbol digit coding test 
(SDC)
FTT taps right hand + FTT 
taps left hand + SDC correct 
responses
Pressing the space bar with the index finger as many 
times in 10 s above mentioned
Reaction Time Stroop test (ST) (ST part II reaction time on 
correct responses + ST part 
III reaction time on correct 
responses) / 2
In part I, pressing the space bar as soon as the words RED, 
YELLOW, BLUE, and GREEN appear—in part II, pressing 
the space bar as the color of the word matches what the 
word says—in part III, pressing the space bar as the color 




mance test (CPT) 
Shifting attention test 
(SAT) 
Stroop test (ST)
Stroop  commission 
errors + SAT errors + CPT 
 commission errors + CPT 
 omission errors
Responding to a target stimulus “B” but no any other 
letter Shifting from one instruction to another quickly and 




Shifting attention test 
(SAT) 
Stroop test (ST)
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performance by assessing the fixed effect of timepoint) 
would result in the factor being incorporated twice in the 
model. All other individual domains were entered into the 
model to examine if there were domains that were consis-
tently predictive for multiple domains (if so, in the future 
a subset of domains could be assessed prior to surgery 
to minimize patient burden). A variance inflation factor of 
over 10 was used as cutoff for multicollinearity in the final 
models.33
Statistical analyses were performed using the Statistical 
Package for the Social Sciences version 24.0 (IBM), except 
for the LMEMs, for which we used the nmle34 package in 
R. To reduce false discovery rate due to multiple statistical 
testing, P-values were set against a corrected alpha, using 
the Benjamini–Hochberg (BH) procedure (leaving greater 
power than the Bonferroni technique).35 When perform-
ing the BH procedure, individual P-values (per hypoth-
esis) were ranked from smallest to largest: the smallest 
P-value has the rank i = 1, the next smallest has i = 2, etc. 
Adjusted P-values were calculated by multiplying the origi-
nal P-value by (m/i), where m is the number of tests, and i 
the rank of the specific P-value. BH-adjusted P-values are 
then compared with the original alpha of 0.05, and the rank 
of the largest adjusted P-value that is smaller than 0.05 is 




Fig. 1 shows the flow of meningioma patients through 
the current study. At T0, 261 patients were included. 
Thirty-two patients (12%) did not complete T3, result-
ing in 229 patients with both T0 and T3. Sixty-four per-
cent of these patients did not undergo T12, mainly 
(in 33%) due to the later implementation of this mea-
surement. Eventually, 82 patients underwent all three 
NPAs. The median time interval between T0 and T3 was 
2.83  months (range 1.00–5.75 months). Median time 
interval between T0 and T12 was 12.42  months (range 
8.51–20.40 months).
Table 2 presents characteristics of the meningioma 
patients. There were no significant differences between 
the T0, T3, and T12 samples regarding sociodemographic, 
clinical, and psychological characteristics. In addition, no 
significant differences were found between the patients 
who underwent T12 and those who did not with regard to 
baseline patient characteristics (Table 2), and T3 cognitive 
performance (ie, the timepoint at which patients decided 
whether or not to participate in T12; data not shown) 
(P values > 0.134).
  
Total number of meningioma patients,
scheduled for clinical pre-surgical




Underwent three months post-
operative neuropsychological
assessment (T3) (N = 229)
Underwent twelve months post-
operative neuropsychological
assessment (Tl2) (N = 82)
Excluded (N = 63):
- unable to undergo the NPA (n = 26)
- history of intracranial neurosurgery (n = 16)
- history (≤2 years) of psychiatric, neurologic, or
major medical illnesses (≤1 year) (n = 9)
- lack of basic proficiency in Dutch (n = 6)
- intraosseous meningioma (n = 6)
Attrition between T0 and T3 (n = 32)
- excluded due to surgical complications (n = 8)
- unable to undergo the NPA (n = 6)
- did not want to participate (n = 6)
- logistic reasons/unknown (n = 5)
- deceased (n = 3)
- surgery cancelled (n = 1)
Attrition between T3 and T12 (n = 147)
- surgery >20 months ago at time of T12 (n = 48)
- did not want to participate/too many other things to
focus on (n = 31)
- logistic reasons/unknown (n = 26)
- participated in cognitive rehabilitation studies (n = 16)
- surgery <12 months ago (n = 13)
- unable to undergo the NPA (n = 11)
- deceased (n = 2)
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Fig. 2 Percentages of meningioma patients with impaired or non-impaired performance over CNS VS cognitive domains at all timepoints. The 
asterisk (*) indicates impairments that were significantly more common in meningioma patients compared with normative controls.
 
Table 2 Baseline sociodemographic, clinical, and psychological characteristics of samples of meningioma patients at each timepoint
Baseline Characteristics T0 (n = 261) T3 (n = 229) T12 (n = 82) Dropout T12 (n = 147)
Sociodemographic characteristics
Age, y: mean ± SD (range) 57.8 ± 11.7 (23–82) 57.1 ± 11.7 (23–82) 55.9 ± 10.7 (32–75) 58.7 ± 12.0 (23–82)
Education, y: mean ± SD (range) 13.7 ± 3.7 (6–26) 14.0 ± 3.7 (6–26) 14.4 ± 3.7 (8–26) 13.5 ± 3.7 (6–22)
Sex: female/male n(%) 189(72)/72(28) 167(73) / 62(27) 59(72) / 23(28) 130(73)/49(27)
Clinical characteristics     
WHO grade: I/II n(%) 240(92) / 21(8) 211(92) / 18(8) 76(93) / 6(7) 164(92)/15(8)
Number of meningioma: 1/≥2 n(%) 244(94) / 17(6) 217(95) / 12(5) 79(96) / 3(4) 168(94)/11(6)
Hemisphere: Left/right/bilateral n(%) 106(41) / 124(48) / 31(11) 94(41) / 107(47) / 28(12) 32(39) / 39(48) / 11(13) 74(41)/85(48)/20(11)
Supratentorial/infratentorial n(%) 238(91) / 23(9) 208(91) / 21(9) 75(91) / 7(9) 163(91) / 16(9)
Frontal/nonfrontal n(%) 154(59) / 107(41) 135(59) / 94(41) 46(56) / 36(44) 108 (60)/71(40)
Tumor volume (cm3): median 
(range)a
33.5 (0.45–150.2) 32.0 (0.45–150.2) 34.5 (0.45–144.8) 32.0 (0.62–150.2)
ASA score: I, II/III, IV n(%) 225(86) / 36(14) 202(88) / 27(12) 71(87) / 11(13) 154(86) / 25 (14)
Psychotropic medication: yes/no 
n(%)b
142(56) / 112(44) 122(54) / 102(46) 45(56) / 35(44) 97 (56) / 77 (44)
Psychological characteristics     
Anxiety HADS: mean ± SD (range)c 7.2 ± 4.2 (0–20) 7.0 ± 4.2 (0–19) 7.0 ± 4.0 (0–17) 7.3 ± 4.3 (0–20)
Depression HADS: mean ± SD 
(range)c
5.9 ± 4.6 (0–21) 5.7 ± 4.5 (0–21) 6.0 ± 4.9 (0–21) 5.8 ± 4.5 (0–19)
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Pre- and Postoperative Cognitive Performance
At T0, percentages of patients with impaired scores 
ranged from 20.4% to 42.4% over domains (Fig. 2). At T3 
and T12 the percentages of patients scoring impaired on 
the cognitive domains respectively ranged from 16.7% to 
32.6%, and from 13.8% to 22.5%. For 6 out of 7 domains 
at T0 and T3, and still 3 out of 7 domains at T12 after sur-
gery, impairments were significantly more common 
in meningioma patients than in normative controls 
(P-values < BH-corrected alpha 0.04; Fig. 2).
We found significantly lower mean performance in patients 
compared with the normative sample on all domains at T0 
(ES ranging from −0.54 to −1.53), T3 (ES from −0.37 to −1.22), 
and T12 (ES from −0.35 to −0.76) (P   values<  BH-corrected 
alpha 0.05; Table 3). At T0 and T3, lowest mean z scores were 
found for Complex Attention (respectively −1.43 and −1.22) 
and Reaction Time (respectively −1.53 and −1.19). At T12, 
lowest mean scores were found for Psychomotor Speed 
(−0.76) and, again, Reaction Time (−0.65).
Changes in Individual and Group Cognitive 
Performance over Time
On the individual level, patients demonstrated improve-
ments more often (ranging 8–28% between T0–T3 and 
3–30% between T3–T12 over different cognitive domains) 
than declines (ranging 3–15% between T0 and T3 and 
1%–15% between T3 and T12) over time (Fig. 3). To com-
pare, 5–6% of the normative sample showed declined 
performance, and another 5–6% showed improved per-
formance over time (ie, RCIs exceeding ± 1.645). Declined 
performance in patients was for none of the domains, nei-
ther over the first nor over the second interval, significantly 
more frequent than in the normative sample, except for 
Reaction Time between T0 and T3 (χ2 (2) = 26.84, P ≤ 0.001) 
and T3 and T12 (χ2 (2) = 28.45, P ≤ 0.001). However, improved 
performance occurred significantly more frequently on 
6 out of 7 domains over the first interval (all domains 
but Verbal Memory), and 4 out of 7 domains (ie, Verbal 
Memory, Reaction Time, Complex Attention, and Cognitive 
Flexibility) over the second interval. Of the 28 patients who 
improved between T3 and T12 (ie, improved on at least 
one cognitive domain, with stable performance on the re-
maining domains), 36% already showed improved perfor-
mance between T0 and T3. Of the 9 patients who showed 
declined performance (ie, declined on at least one cogni-
tive domain, with stable performance on the remaining 
domains) between T3 and T12, 11% had already declined 
between T0 and T3.
The final LMEMs demonstrated changes in cognitive 
performance on the group level, as shown in Table 4. 
Patients’ performance improved significantly over the first 
time interval on 3 domains, namely Processing Speed, 
Psychomotor Speed, and Reaction Time (respectively 
B = 0.22, SE = 0.07, P = 0.002; B = 0.42, SE = 0.08, P < 0.001; 
B = 0.33, SE = 0.13, P = 0.013). Verbal Memory performance 
was found to decline significantly (B  =  −0.22, SE  =  0.09, 
P = 0.018), and no significant changes were found for Visual 
Memory, Complex Attention, and Cognitive Flexibility (re-
spectively B = 0.19, SE = 0.09, P = 0.038; B = 0.25, SE = 0.15, 
P  =  0.095; and B  =  0.21, SE  =  0.12, P  =  0.079). Over the 
second interval, significantly improved performance was 
found for 4 out of 7 domains. No changes were found be-
tween T3 and T12 on Verbal Memory (B = 0.26, SE = 0.13, 
P = 0.044), Visual Memory (B = −0.10, SE = 0.12, P = 0.398), 
and Psychomotor Speed (B = 0.02, SE = 0.09, P = 0.864).
Predictors of Late Cognitive Impairment
Table 4 shows the final LMEMs for the cognitive domains. 
Older age and Cognitive Flexibility score at T0 were sig-
nificantly associated with a lower z score on Complex 
Attention at T12. Male sex and higher T0 Psychomotor 
Speed performance were significantly predictive for higher 
scores on Processing Speed. A high educational level and 
better T0 Processing Speed performance significantly pre-
dicted a higher Psychomotor Speed score. Higher T0 Verbal 
Memory performance significantly predicted higher Visual 
Memory scores, and vice versa, higher T0 Visual Memory 
performance predicted higher Verbal Memory z scores. 
Higher performance on Reaction Time and Complex 
Attention at T0 were significantly predictive of higher 
Cognitive Flexibility scores (P  values < BH-corrected alpha 
 
Table 3 Cognitive performance on CNS VS domains of meningioma patients compared with the normative sample
T0 T3 T12
Domain z Scorea 
M(SD)
z test z Scorea M(SD) z test  z Scorea M(SD) z-Test
Verbal Memory −0.67(1.30) −10.38* −0.90(1.35) −13.50* −0.59(1.19) −5.29*
Visual Memory −0.54(1.23) −8.35* −0.37(1.26) −5.52* −0.35(1.14) −3.09*
Processing Speed −1.11(1.36) −17.39* −0.85(1.22) −12.75* −0.58(0.99) −5.22*
Psychomotor Speed −1.31(1.66) −20.45* −0.93(1.36) −13.95* −0.76(1.14) −6.72*
Reaction Time −1.53(2.38) −23.79* −1.19(2.02) −17.83* −0.65(1.61) −5.81*
Complex Attention −1.43(2.60) −21.61* −1.22(2.29) −18.06* −0.61(1.92) −5.43*
Cognitive Flexibility −1.34(2.28) −20.69* −1.12(1.79) −16.62* −0.48(1.46) −4.34*
*P < BH-corrected alpha 0.05.
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0.005). None of the preoperatively known clinical or psy-
chological variables, nor the number of months between T0 
and T12, were found to significantly predict performance at 
T12 (P  values > BH-corrected alpha 0.005).
The variance explained (ie, marginal R2) ranged from 
3% to 14% when only sociodemographic variables were 
included in the LMEM as fixed effects, from 5% to 22% 
when clinical variables were added, from 7% to 22% when 
psychological variables were added, and from 24% up to 
85% when the cognitive variables were added to the mod-
els (data not shown).
Discussion
In general, preoperative cognitive deficits have been doc-
umented in patients with meningioma, and a number of 
studies suggested that patients also show postoperative 
impairments.2–11 Prospective studies including preop-
erative assessments as well as analyses on the individual 
level, however, are still lacking.
We found extensive preoperative as well as 3- and 
12-month postoperative cognitive deficits in our large 
sample of meningioma patients: mean performance of 
patients was significantly lower on all cognitive domains 
at all three timepoints compared to the normative sample 
with predominantly large, but also medium, effect sizes. 
On the individual patient level, impairments were sig-
nificantly more common in meningioma patients com-
pared with normative controls on 6 out of 7 domains at 
T0 and T3, and on 3 out of 7 domains at T12. Performance 
on Psychomotor Speed, Reaction Time, and Complex 
Attention was most frequently, as well as most severely, 
impaired. A  prior study demonstrated significant predic-
tive value of cognitive functioning with regard to functional 
independence in patients with glioma, providing evidence 
that cognitive functioning, assessed with neuropsycho-
logical tests, can be translated into “real-world” functions 
and activities.36 The patients in our study may, for example, 
have difficulty with the agility and adequacy of movements 
(related to Psychomotor Speed), may respond slowly to 
stimuli (related to Reaction Time), and may struggle to 
adapt behaviors and thoughts to new, changing, or unex-
pected events (related to Complex Attentions, but also to 
higher order executive functions). These problems compli-
cate (and might even endanger) the ability to perform eve-
ryday activities, such as driving a car or preparing dinner. 
The results of the current study add support for the imple-
mentation of routine NPAs in the clinical management of 
meningioma patients to monitor and deal with common 
and serious cognitive deficits in order to maximize quality 
of life and functional independence in home, work, and so-
cial settings.
The results indicate that cognitive performance on the 
group level improves over time. Over the first time interval 
we found significant improvements on Processing Speed, 
Psychomotor Speed, and Reaction Time. Further improved 
performance was found for Processing Speed, Reaction 
Time, Complex Attention, and Cognitive Flexibility over the 
second time interval. Yet, as it is expected that some patients 
show improved and other patients show declined perfor-
mance, mean group results may mask changes in individual 
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Fig. 3 Changes in cognitive performance of individual meningioma patients. The asterisk (*) indicates changes that were significantly more 
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performance in 1‒15% and 3‒30% of the patients over the 
different cognitive domains over the two time intervals. The 
overlap of patients with solely improved or declined perfor-
mance between both T0–T3 and T3–T12 was rather small (ie, 
respectively 36% and 11% of the patients improving and de-
clining over both intervals), suggesting that changes over 
the second interval in most cases are not continuations of 
changes in the previous interval. Furthermore, the propor-
tion of “decliners” was for none of the domains, nor for 
the two intervals, significantly larger than in the normative 
sample, except for Reaction Time over both intervals. In 
contrast, improvements were significantly more common 
 















 Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE) Β (SE)
Interval T0-T3a −0.22 (0.09) 0.19 (0.09) 0.22 (0.07) 0.42 (0.08) 0.33 (0.13) 0.25 (0.15) 0.21 (0.12)
Interval T3-T12 a 0.26 (0.13) −0.10 (0.12) 0.21 (0.07) 0.01 (0.09) 0.49 (0.18) 0.49 (0.18) 0.53 (0.10)
Months T0-T12b 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Sociodemographic variables       
Ageb 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) −0.01 (0.01) −0.02 (0.01) −0.02 (0.01) −0.00 (0.01)
Sexb        
female (vs men) 0.15 (0.20) −0.46 (0.18) −0.53 (0.15) 0.05 (0.16) 0.37 (0.30) 0.05 (0.19) 0.24 (0.14)
Educationb        
 middle (vs low) −0.02 (0.20) 0.16 (0.18) 0.06 (0.16) −0.21 (0.17) 0.22 (0.31) −0.06 (0.20) 0.01 (0.14)
 high (vs low) 0.44 (0.21) 0.08 (0.19) −0.03 (0.17) 0.53 (0.17) 0.40 (0.33) 0.41 (0.21) −0.27 (0.15)
Clinical variables        
Hemisphereb        
 right (vs left) −0.08 (0.17) −0.15 (0.15) −0.14 (0.13) −0.26 (0.14) −0.14 (0.25) 0.03 (0.16) 0.20 (0.12)
Supratentorialb        
 yes (vs no) 0.16 (0.29) 0.50 (0.26) −0.27 (0.23) −0.37 (0.24) 0.24 (0.45) 0.13 (0.29) −0.13 (0.21)
Frontalb        
 yes (vs no) −0.11 (0.17) −0.40 (0.16) −0.19 (0.14) −0.11 (0.14) 0.13 (0.27) 0.27 (0.17) 0.03 (0.13)
Multipleb        
 yes (vs no) 0.10 (0.35) 0.41 (0.32) 0.18 (0.28) −0.48 (0.30) 0.25 (0.54) −0.01 (0.34) 0.15 (0.25)
Volume mmbc 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
ASA scoreb        
 >3 (vs 1 or 2) 0.43 (0.24) −0.23 (0.22) 0.07 (0.19) −0.51 (0.20) −0.11 (0.38) −0.19 (0.24) 0.36 (0.17)
Medicationbd        
 yes (vs no) −0.06 (0.17) −0.25 (0.15) −0.24 (0.13) 0.01 (0.14) 0.03 (0.26) −0.22 (0.17) 0.21 (0.12)
Psychological 
variables
       
HADS Abe 0.01 (0.02) −0.05 (0.02) −0.03 (0.02) −0.04 (0.02) 0.01 (0.04) −0.01 (0.02) −0.00 (0.02)
HADS Dbe −0.01 (0.02) 0.02 (0.02) 0.03 (0.02) 0.03 (0.02) −0.04 (0.03) 0.01 (0.02) −0.01 (0.02)
Cognitive variables        
Verbal Memoryb − 0.31 (0.06) 0.04 (0.06) 0.02 (0.06) 0.09 (0.11) 0.04 (0.07) −0.07 (0.05)
Visual Memoryb 0.40 (0.07) — −0.09 (0.06) 0.05 (0.06) 0.02 (0.12) 0.07 (0.08) 0.06 (0.06)
Processing Speedb 0.01 (0.09) −0.09 (0.08) — 0.34 (0.06) 0.17 (0.14) 0.05 (0.09) 0.15 (0.07)
Psychomotor Speedb 0.12 (0.08) 0.09 (0.08) 0.39 (0.05) — 0.18 (0.13) −0.16 (0.08) 0.05 (0.06)
Reaction Timeb −0.01 (0.05) −0.03 (0.04) 0.01 (0.04) 0.02 (0.04) — −0.04 (0.05) 0.11 (0.03)
Complex Attentionb 0.08 (0.09) 0.05 (0.08) 0.02 (0.07) −0.10 (0.07) −0.09 (0.13) — 0.59 (0.03)
Cognitive Flexibilityb −0.08 (0.11) 0.06 (0.10) 0.18 (0.09) 0.23 (0.09) 0.44 (0.17) 1.05 (0.05) —
a in bold: P < BH-corrected alpha .03.
b in bold: P < BH-corrected alpha .005.
c data missing for n = 6; d data missing for n = 6; e data missing for n = 7.
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in meningioma patients (compared with the normative 
sample) for most domains over the first interval, and over 
half of the domains over the second interval. Improvements 
of performance over time were most frequent and largest 
for the domains that were most frequently and severely im-
paired at T0, namely Reaction Time, Psychomotor Speed, 
and Complex Attention. It should be recognized that very 
low baseline performance leaves the most room for im-
provement. However, as the far majority of patients shows 
stable performance over time and regression to the mean is 
controlled for by using RCIs, it is likely that an overall small 
to moderate improvement among many patients explains 
the significant group-level improvements on these domains, 
instead of a small group of patients with large improve-
ments. Furthermore, it should be noted that postoperative 
improvements do not imply that performance of patients 
returns to unimpaired levels: group performance was still 
significantly lower on all domains compared with the nor-
mative sample; and in addition, about 13% up to almost a 
quarter of the patients showed impaired performance over 
different domains at T12.
The LMEMs showed that preoperative cognitive per-
formance was the best predictor for late cognitive per-
formance, and sociodemographic characteristics were 
predictive for cognitive outcomes. Younger age, male sex, 
and a higher education were predictors of better perfor-
mance on some domains 12 months after surgery, while 
sociodemographically corrected z scores28 were used. 
These findings can be partly related to the concept of 
cognitive reserve. Cognitive reserve posits cognitive pro-
cesses—consisting of differences in cognitive efficiency, 
capacity or flexibility shaped by, for example, education, 
socioeconomic status, and life experiences—as explana-
tion of differences between patients who are function-
ally impaired and patients who are not, despite equal 
brain pathologies.37–39 The finding of additional predictive 
effects of age and education, factors that are both associ-
ated with cognitive reserve,39 suggests that these variables 
play a larger role in meningioma patients than in healthy 
controls. Neither the clinical nor the psychological vari-
ables appeared to have significant predictive value for 
late cognitive performance. Mixed results have been dem-
onstrated in previous studies with regard to the location 
and volume of meningioma in relation to cognitive perfor-
mance; whereas some studies demonstrated no significant 
effects,2 others demonstrated, for example, more deficits 
in patients with frontal meningioma.12,13,15,20 Meningioma 
indeed yield local effects because of its mass effect on 
the surrounding healthy brain.2,20 Consequently, this will 
likely also reduce the functional integrity of remote brain 
regions, as locally compressed brain areas and white mat-
ter pathways are densely connected to other parts of the 
brain.40 This would explain why tumor location and volume 
are not very strong predictors of long-term cognition, as 
cognition is considered to be globally rather than locally 
represented in the brain. Results of the current study also 
suggest that preoperative mood is not a predictor for cog-
nitive outcome. Yet, some (small) associations between 
mood and cognitive performance after surgery in (partly) 
the same sample were demonstrated before.9 A  periop-
erative increase of anxiety and depression can be a very 
normal reaction to the diagnosis with and major treatment 
of a meningioma; however, it is not very likely that this 
increase is also related to late cognitive deficits.
Our psychometric studies on CNS VS in healthy con-
trols have led us to develop and use sociodemographically 
adjusted z scores, as well as RCIs with correction for prac-
tice effects when interpreting performance on CNS VS.28,29 
However, CNS VS was assumed to be suitable for serial 
administration without inducing practice effects at time of 
the previous study in meningioma patients.9,27 It should 
therefore be noted that the observed severity of cognitive 
deficits of meningioma patients in that previous study was 
possibly underestimated. In addition, improvement due to 
practice effects may have overwhelmed effects of “true” 
change, and may have contributed to the observed improve-
ment in test performance in the former patient group.9
The current study has some limitations that should be 
noted. We solely included patients who were considered 
acceptable candidates for surgery and capable of under-
going the preoperative NPA. Consequently, results may 
be biased towards an overestimation of cognitive per-
formance in meningioma patients in general. Also, one 
should take into account that T12 was (as opposed to T0 
and T3) no longer part of clinical neuro-oncological care. 
As this assessment was implemented about 4 years after 
the start of the study, for a significant proportion of the T3 
sample (ie, 33%) more than 21 months had already passed 
since surgery for these patients, and those were excluded. 
A considerably smaller number of patients (21%) dropped 
out because they were not motivated to participate. 
Comparisons of baseline characteristics of the samples 
included at T0, T3, and T12 suggest that there were no differ-
ences between patients who completed the assessments. It 
is therefore unlikely that the patients we evaluated formed 
a very specific group. Furthermore, it would have been 
interesting to predict group membership (ie, declined, 
stable, improved) instead of predicting late performance. 
However, as the percentages of patients with declined or 
improved performance ranged from 1% to 15% at most 
across the different domains, these numbers were not suf-
ficient to carry out statistical prediction analysis on group 
membership at T12. We chose to predict late performance, 
as this also provides clinically meaningful information of 
longer-term cognitive outcome at an early stage. Finally, 
it is important to mention that CNS VS is somewhat lim-
ited in terms of covering all cognitive functions: language 
and visuospatial abilities, for example, are not assessed. 
Yet, in order to systematically assess and not overburden 
patients who are part of a carefully defined clinical path, 
we designated CNS VS as a good alternative to extensive 
(and therefore costly and time-consuming) NPA.
Increasing attention is being paid to rehabilitation in 
meningioma patients. A  former randomized controlled 
trial (RCT) by Zucchella et al41 showed immediate posi-
tive effects of cognitive rehabilitation in the first weeks 
after surgery on cognitive performance in a sample of 
neuro-oncological patients, including meningioma 
patients. However, as this study did not include a lon-
ger-term follow-up, it remains unknown whether these 
effects persist. More recently, feasibility of and patient 
satisfaction with an iPad-based cognitive rehabilitation 
program 3 months after surgery was demonstrated in a 
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and meningioma.18 An RCT on the effects of this pro-
gram on (among others) cognitive performance in a 
larger sample is currently ongoing.19 The increasing 
opportunities for rehabilitation of cognition demand 
knowledge of characteristics of meningioma patients 
who are at high risk of cognitive deficits after surgery, 
as presented by the current study. We found deficits in 
a broad range of cognitive domains in many patients; 
therefore, we recommend that cognitive rehabilitation 
should at least offer psychoeducation about cognitive 
functioning (which can be easily accessible for many 
patients) and teaching of compensatory skills (including 
strategies and exercises—for example, to try to focus on 
one task at a time and to outline steps required to com-
plete a task before beginning it) in order to effectively 
address the widespread deficits.
To conclude, although performance improved over time 
on the group level in our large sample of meningioma 
patients, the majority of individual patients showed stable 
cognitive functioning, and cognitive scores still remained 
significantly lower than in healthy controls up to 12 months 
after surgery. Our study indicates that a preoperative NPA, 
together with easily available sociodemographic informa-
tion, may provide valuable information on the late cognitive 
outcome of individual meningioma patients. This knowledge 
can help to inform patients and clinicians on late cognitive 
status at an early stage. In addition, it emphasizes the impor-
tance of presurgical NPA, and of timely rehabilitation in me-
ningioma patients who are at risk for cognitive impairment.
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